Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review

Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review

Background/aimHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advance...

Full description

Bibliographic Details
Main Authors:	Yang Li, Jingjiao Zhang, Zhengang Cai, Xue Gao, Lina Zhang, Zhi Lu, Xiaojie Wang, Peiyao Yu, Jia Li, Fengqi Fang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Subjects:	Disitamab Vedotin (RC48) advanced breast cancer human epidermal growth factor receptor 2 targeted therapy tumor resistance case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1286392/full

Similar Items

mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation
by: Ye Hu, et al.
Published: (2024-01-01)

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
by: Fan Shi, et al.
Published: (2022-12-01)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
by: Xiangjun Qi, et al.
Published: (2022-09-01)

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
by: Haijun Huang, et al.
Published: (2023-04-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study
by: Jingwei Xu, et al.
Published: (2023-12-01)

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report
by: Fei Qu, et al.
Published: (2023-08-01)

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study
by: Caiyun Nie, et al.
Published: (2023-12-01)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
by: Yongbao Wei, et al.
Published: (2023-08-01)

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
by: Jiazheng Yu, et al.
Published: (2024-05-01)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
by: Andrea Francis, BS, et al.
Published: (2021-01-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
by: Zhenying Xu, et al.
Published: (2022-11-01)

RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
by: Ping Wang, et al.
Published: (2023-11-01)

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer
by: Xuwei Hong, et al.
Published: (2023-11-01)

The successful management of SJS/TEN secondary to enfortumab vedotin therapy
by: Rhea Singh, BS, et al.
Published: (2022-06-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01)

Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report
by: Jordan Senchak, et al.
Published: (2016-09-01)

Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024-04-01)

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy
by: CHAI Xiaofei, et al.
Published: (2023-03-01)

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
by: Yue Zheng, et al.
Published: (2023-10-01)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023-07-01)

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)
by: Feng Wen, et al.
Published: (2024-01-01)

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
by: Zhi Peng, et al.
Published: (2021-11-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
by: Moussa M, et al.
Published: (2021-02-01)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
by: Jain RK, et al.
Published: (2020-09-01)

Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
by: Xudong Zhang, et al.
Published: (2023-12-01)

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
by: Thibodeau A, et al.
Published: (2021-10-01)

Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report
by: Zhuixing Liu, et al.
Published: (2024-02-01)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023-03-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trialResearch in context
by: Yakun Wang, et al.
Published: (2024-02-01)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01)

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
by: Merve Hasanov, et al.
Published: (2020-08-01)

Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
by: Abdur Raqib M, et al.
Published: (2023-10-01)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
by: Rita Assi, et al.
Published: (2021-03-01)